Last updated: 22 June 2019 at 2:37am EST

Charles A Baker Net Worth




The estimated Net Worth of Charles A Baker is at least $12.6 Milion dollars as of 29 September 2017. Charles Baker owns over 2,000 units of Regeneron Pharmaceuticals stock worth over $12,555,950 and over the last 22 years Charles sold REGN stock worth over $0.

Charles Baker REGN stock SEC Form 4 insiders trading

Charles has made over 23 trades of the Regeneron Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. Most recently Charles exercised 2,000 units of REGN stock worth $37,220 on 29 September 2017.

The largest trade Charles's ever made was exercising 27,500 units of Regeneron Pharmaceuticals stock on 1 April 2003 worth over $146,575. On average, Charles trades about 4,532 units every 113 days since 2003. As of 29 September 2017 Charles still owns at least 11,000 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Charles Baker stock trades at the bottom of the page.



What's Charles Baker's mailing address?

Charles's mailing address filed with the SEC is RD 2 BOX 4830 PROVINCE LANE, , PRINCETON, NJ, 08540.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis oraz Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.



What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.



Complete history of Charles Baker stock trades at Progenics Pharmaceuticals i Regeneron Pharmaceuticals

Osoba
Trans.
Transakcja
Łączna cena
Charles A Baker
Dyrektor
Opcja Ćwiczenie $37,220
29 Sep 2017
Charles A Baker
Dyrektor
Opcja Ćwiczenie $55,830
12 Dec 2016
Charles A Baker
Dyrektor
Opcja Ćwiczenie $55,830
12 Dec 2016
Charles A Baker
Dyrektor
Opcja Ćwiczenie $93,050
17 Sep 2015
Charles A Baker
Dyrektor
Opcja Ćwiczenie $93,050
25 Mar 2015
Charles A Baker
Dyrektor
Opcja Ćwiczenie $357,600
24 Mar 2014
Charles A Baker
Dyrektor
Opcja Ćwiczenie $295,350
30 Sep 2013
Charles A Baker
Dyrektor
Opcja Ćwiczenie $237,000
10 Jun 2013
Charles A Baker
Dyrektor
Opcja Ćwiczenie $137,550
26 Nov 2012
Charles A Baker
Dyrektor
Opcja Ćwiczenie $225,150
5 Sep 2012
Charles A Baker
Dyrektor
Opcja Ćwiczenie $282,000
17 Apr 2012
Charles A Baker
Dyrektor
Opcja Ćwiczenie $115,240
10 Aug 2011
Charles A Baker
Dyrektor
Opcja Ćwiczenie $316,910
1 Jul 2011
Charles A Baker
Dyrektor
Opcja Ćwiczenie $127,150
2 Jun 2010
Charles A Baker
Dyrektor
Opcja Ćwiczenie $76,600
20 Feb 2009
Charles A Baker
Dyrektor
Opcja Ćwiczenie $79,100
15 Feb 2008
Charles A Baker
Dyrektor
Opcja Ćwiczenie $16,006
16 Feb 2007
Charles A Baker
Dyrektor
Opcja Ćwiczenie $82,794
16 Feb 2007
Charles A Baker
Dyrektor
Opcja Ćwiczenie $120,000
1 Feb 2006
Charles A Baker
Dyrektor
Opcja Ćwiczenie $61,300
22 Feb 2005
Charles A Baker
Dyrektor
Opcja Ćwiczenie $70,000
2 Feb 2004
Charles A Baker
Dyrektor
Opcja Ćwiczenie $48,750
29 Jan 2007
Charles A Baker
Dyrektor
Opcja Ćwiczenie $146,575
1 Apr 2003


Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: